Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Bimekizumab improves joint measures in patients with active psoriatic arthritis and moderate or severe psoriasis: Pooled 16-week results from phase 3 randomized, placebo-controlled studies BE OPTIMAL and BE COMPLETE

Alice B. Gottlieb,Akihiko Asahina,Joseph F. Merola,Iain B. McInnes,Wolf-Henning Boehncke,Mark Lebwohl,Diamant Thaci,Barbara Ink,Rajan Bajracharya,Jason Coarse,Richard B. Warren

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT（2023）

Cited 0|Views5
No score
Abstract
Background: Understanding efficacy of biologic treatments in joints in patients with psoriatic arthritis (PsA) and increasing amounts of psoriasis-affected BSA is of interest to clinicians.[1] Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has demonstrated efficacy and tolerability up to 16 wks in patients with PsA.[2-3]
More
Translated text
Key words
active psoriatic arthritis,psoriatic arthritis,severe psoriasis,bimekizumab,placebo-controlled
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined